Rezolute, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Redwood city, calif., april 23, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “an analysis of overnight hypoglycemia in patients with congenital hyperinsulinism: results from the rz358-606 (rize) study” will be presented at the pediatric endocrine society (pes) annual meeting, to be held may 2-5, 2024 at the sheraton grand chicago riverwalk.

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)

Phase 3 clinical study of rz358 underway in patients with congenital hyperinsulinism (chi); topline results expected in mid-2025

Redwood city, calif., jan. 24, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of daron evans, ms, mba, to its leadership team as chief financial officer as well as the grant of share options as a material inducement for his appointment (the “inducement grant”).

Redwood city, calif., jan. 23, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the u.k. medicines and healthcare products regulatory agency (mhra) has awarded the innovative medicine designation, the innovation passport, to rz358 for the treatment of hypoglycemia due to congenital hyperinsulinism (hi). the innovation passport designation was granted based on the substantial unmet medical need in this condition and the potential for rz358 to benefit patients as evidenced by the phase 2 rize study in congenital hi, which safely demonstrated significant improvements in hypoglycemia events.

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.

Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperinsulinism, a condition characterized by excessive insulin production. The Company is trading for 50% of cash, about to initiate a phase 3 study in an ultra-orphan indication, with significant potential upside on a valuation basis.

REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in two upcoming investor conferences.

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.

Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant.

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Concurrently with the public offering and by means of a prospectus supplement and accompanying prospectus, Rezolute is offering to sell shares of its common stock directly to certain institutional investors that are current shareholders, in a registered direct offering.

Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full year ended June 30, 2021.